On September 11, 2024, Kristiina Vuori, Director at Inhibrx Biosciences Inc (INBX, Financial), acquired 6,636 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now directly owns 13,776 shares of the company.
Inhibrx Biosciences Inc (INBX, Financial) is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. The company aims to address significant unmet medical needs in oncology, orphan diseases, and infectious diseases.
Over the past year, the insider transaction history at Inhibrx Biosciences Inc (INBX, Financial) shows a trend of more insider buying than selling. There have been nine insider buys and zero insider sells. This recent purchase by Director Kristiina Vuori aligns with the ongoing trend of insider confidence in the company's prospects.
On the date of the insider's recent purchase, shares of Inhibrx Biosciences Inc were trading at $15.07 each. The company's market cap was approximately $217.428 million, reflecting its size and the market's valuation of the firm.
For more detailed valuation metrics of Inhibrx Biosciences Inc, such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can refer to the respective links.
This insider buy might interest investors as it could signal a positive outlook from the insider regarding the company's future performance. For more insights and valuation metrics, investors can check the GF Value of Inhibrx Biosciences Inc (INBX, Financial).
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
